The centaur variant or BA.2.75, one of the sublines of the omicrom variant of Covid-19, which could be five to seven times more contagious than its predecessors, has already registered a first case in Peru, more precisely in the metropolis of Lima.
In a press release from Ministry of Health of Peru The patient is said to be stable. “There are no concerning variations in his condition, he does not require hospitalization and is under continuous observation and evaluation.”
What symptoms did you show?
He presented the first symptoms of COVID-19. The patient went to a health center and is currently being monitored to find out the evolution of his state of health.
Centaur symptoms, according to intensive care physician Alberto Campodónico, last about three to four days.
However, the expert points out that the consequences of this still need to be studied. “After the incubation of the virus, the symptoms already appear”, he said in an interview with Metro Ecuador.
Centaurus shares most symptoms with the “variant sister” omicron.
- Sore throat.
- Runny nose.
- Loss of taste and smell (these are less common).
On the centaur variant
The centaur variant was identified in May this year in India. Scientists say it could spread quickly and bypass immunity from previous vaccinations and infections. It is unclear whether it could cause more severe disease than other omicron variants, such as BA.5, which are prevalent worldwide.
World Health Organization (WHO), through its chief scientist in India, Soumya Swaminatahn, warned that “there has been a emergency for – what could be – a new sub-variant”. The Asian country was the first to report its detection and is where most of the cases detected so far are concentrated.
In India represents at least 23% of infections sequenced Yes growing at a rate of 17% per day faster than the rest of the variants of the BA.2 lineage, according to government data from that country.
Five times more infectious than Omicron
The WHO reports that the centaur variant is five times more contagious than Omicron. Through the agency’s official Twitter account, Dr. Soumya Swaminathan states that “it is still too early to know if this variant has more ability to evade the immune system or if it causes more serious illness, but we are monitoring these aspects closely.